He is leading the world's first clinical trial assessing MRI-guided focused ultrasound for targeted delivery of anti-cancer drugs to the brain. In November 2015, Mainprize and his team successfully bypassed a patient’s blood-brain barrier using the focused ultrasound brain device that was developed by Dr. Kullervo Hynynen. He is a faculty member in the department of surgery at the University of Toronto.